BioStock Investor Pitch: SynAct Pharma

SynAct Pharma develops new treatments for inflammatory diseases by selectively activating the melanocortin system. 2021 was an important year for the company with several milestones achieved and positive clinical data for the candidate AP1189 in two indications. The company is now conducting a rights issue of SEK 150 million to finance further clinical phase II development in primarily rheumatoid arthritis. At the same time, discussions with potential partners continue. CEO Jeppe Øvlesen will talk more about SynAct Pharma's vision in today's BioStock Investor Pitch at 10:00.